New drug LAD191 put to the test: first human safety check begins
NCT ID NCT06488209
First seen Nov 25, 2025 · Last updated May 01, 2026 · Updated 15 times
Summary
This early-stage study tested the safety and tolerability of a new drug, LAD191, in 69 adults—some healthy and some with an autoimmune disease. The main goal was to see if the drug causes side effects and how the body processes it. No treatment benefits were expected; this was purely a safety and dosing study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Doral Medical Research
Miami, Florida, 33165, United States
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78209, United States
-
Jennifer Parish, MD
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.